Valo Health appointed Karin Conde-Knape, Ph.D., as Chief Scientific Officer (CSO) on February 3, 2026.
Dr. Conde-Knape joins from Novo Nordisk, where she served as Senior Vice President of Early Development and Global Drug Discovery, bringing over 20 years of expertise in drug development and translational science.
She succeeds Mike Graziano, Ph.D., who is retiring and transitioning to Scientific Advisor.
At Valo, she will oversee scientific strategy for internal programs and global collaborations using AI-enabled platforms.
Valo Health uses AI and human data to accelerate drug discovery, founded in 2019 by Flagship Pioneering.
Novo Nordisk has had a collaborative agreement with Valo since 2023.